NCT02220712View on ClinicalTrials.gov

A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Schizophrenia
Interventions
DRUG

OPC-14597 IMD

Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals

Trial Locations (5)

Unknown

Chugoku Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushu Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT02220712 - A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter